Separately, Citigroup increased their target price on Bio-Rad Laboratories from $480.00 to $525.00 and gave the stock a buy rating in a research note on Thursday, May 7th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Bio-Rad Laboratories has a consensus rating of Buy and a consensus target price of $511.25.
Shares of Bio-Rad Laboratories stock opened at $524.89 on Thursday. Bio-Rad Laboratories has a one year low of $307.39 and a one year high of $540.06. The company has a market cap of $15.56 billion, a P/E ratio of 8.14 and a beta of 1.08. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.76 and a current ratio of 2.40. The firm has a fifty day moving average of $474.38 and a two-hundred day moving average of $419.24.
Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Thursday, July 30th. The medical research company reported $1.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.39. The business had revenue of $536.88 million for the quarter, compared to analyst estimates of $526.80 million. Bio-Rad Laboratories had a net margin of 84.89% and a return on equity of 3.92%. As a group, equities analysts predict that Bio-Rad Laboratories will post 7.2 earnings per share for the current year.
In other Bio-Rad Laboratories news, VP Ronald W. Hutton sold 443 shares of the business’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $457.35, for a total transaction of $202,606.05. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Michael Crowley sold 1,500 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $485.40, for a total value of $728,100.00. Following the sale, the executive vice president now owns 2,310 shares in the company, valued at $1,121,274. The disclosure for this sale can be found here. 27.50% of the stock is currently owned by insiders.
Several large investors have recently added to or reduced their stakes in BIO. FMR LLC increased its holdings in Bio-Rad Laboratories by 12.7% during the 1st quarter. FMR LLC now owns 182,762 shares of the medical research company’s stock valued at $55,867,000 after acquiring an additional 20,560 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of Bio-Rad Laboratories by 1.4% during the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,968 shares of the medical research company’s stock worth $733,000 after purchasing an additional 28 shares in the last quarter. Standard Life Aberdeen plc acquired a new position in shares of Bio-Rad Laboratories during the 4th quarter worth approximately $422,000. Geode Capital Management LLC lifted its stake in Bio-Rad Laboratories by 5.4% in the 4th quarter. Geode Capital Management LLC now owns 242,986 shares of the medical research company’s stock valued at $89,827,000 after buying an additional 12,340 shares in the last quarter. Finally, Norges Bank acquired a new stake in Bio-Rad Laboratories during the 4th quarter valued at $78,177,000. 62.89% of the stock is owned by institutional investors and hedge funds.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.
Featured Story: How to trade on quiet period expirations
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.